mercaptopurine | mercaptopurine tablets 50 mg 25 pcs. pack
Special Price
$29.10
Regular Price
$37.00
In stock
SKU
BID480825
Latin name
Mercaptopurin
Mercaptopurin
Latin name
Mercaptopurin
Release form
tablets
Packaging
25 pcs
Pharmacological action
Mercaptopurin has an antitumor, immunosuppressive effect.
Indications
Acute lymphoblastic leukemia, acute myelogenous leukemia (including acute myelocytic leukemia), exacerbation of chronic myelogenous leukemia, uterine chorionepithelioma, reticulosis, chronic granulocytic leukemia.
Contraindications
Hypersensitivity, tumor resistance, inhibition of bone marrow function (leukopenia with a white blood cell count less than 3 · 109 / l, thrombocytopenia with a platelet count less than 100 · 109 / l), chickenpox, shingles and other infections, a history of kidney, gout, or kidney stone disease.
Use during pregnancy and lactation
Contraindicated in pregnancy. The use of mercaptopurine during pregnancy was accompanied by an increased risk of miscarriage or premature birth.
Breastfeeding should be discontinued during treatment.
Composition of
1 tablet contains:
Active ingredient: mercaptopurine 50 mg
Dosage and administration of
mercaptopurine is taken orally. For adults and children, the initial oral dose is 2.5 mg / kg / day or 80-100 mg / m2 (on average, 100-200 mg for adults, 50 mg for children 5 years of age). It is possible to increase the dose to 5 mg / kg / day (no more) for 4 weeks. Maintenance dose: 1.5-2.5 mg / kg or 50-100 mg / m2 per day. Patients with hepatic and / or renal failure reduce the dose. When administered concomitantly with allopurinol (300-600 mg / day), only 1 / 3-1 / 4 of the usual dose of mercaptopurine is used (decrease in metabolic rate due to xanthine oxidase blockade).
The daily dose of mercaptopurine is usually used once.
Also used in combination chemotherapy.
Side effects
From the nervous system and sensory organs: headache, weakness.
From the side of the cardiovascular system and blood: most often anemia, leukopenia, thrombocytopenia (during the period of active therapy for acute myelogenous leukemia in patients, a period of relative bone marrow aplasia is often noted, while it is important to carry out appropriate supportive treatment).
From the gastrointestinal tract: nausea, vomiting, diarrhea, loss of appetite, hepatotoxic effect (has a toxic allergic genesis and more often occurs when a dose is higher than 2.5 mg / kg / day) or cholestasis (scleral or skin yellowness) rarely - stomatitis ( usually at high doses), ulcerations in the digestive tract, hepatic encephalopathy.
From the genitourinary system: less often - hyperuricemia or nephropathy.
From the skin: hyperpigmentation of the skin, skin rash, itching.
Other: decreased immunity and susceptibility to infections.
Storage conditions
In the dark place at a temperature of no higher than 20 РC.
Term hodnosty
5 years
Deystvuyuschee substances
mercaptopurine
pharmacy terms of prescription
Form of Treatment
tablets
Mercaptopurin
Release form
tablets
Packaging
25 pcs
Pharmacological action
Mercaptopurin has an antitumor, immunosuppressive effect.
Indications
Acute lymphoblastic leukemia, acute myelogenous leukemia (including acute myelocytic leukemia), exacerbation of chronic myelogenous leukemia, uterine chorionepithelioma, reticulosis, chronic granulocytic leukemia.
Contraindications
Hypersensitivity, tumor resistance, inhibition of bone marrow function (leukopenia with a white blood cell count less than 3 · 109 / l, thrombocytopenia with a platelet count less than 100 · 109 / l), chickenpox, shingles and other infections, a history of kidney, gout, or kidney stone disease.
Use during pregnancy and lactation
Contraindicated in pregnancy. The use of mercaptopurine during pregnancy was accompanied by an increased risk of miscarriage or premature birth.
Breastfeeding should be discontinued during treatment.
Composition of
1 tablet contains:
Active ingredient: mercaptopurine 50 mg
Dosage and administration of
mercaptopurine is taken orally. For adults and children, the initial oral dose is 2.5 mg / kg / day or 80-100 mg / m2 (on average, 100-200 mg for adults, 50 mg for children 5 years of age). It is possible to increase the dose to 5 mg / kg / day (no more) for 4 weeks. Maintenance dose: 1.5-2.5 mg / kg or 50-100 mg / m2 per day. Patients with hepatic and / or renal failure reduce the dose. When administered concomitantly with allopurinol (300-600 mg / day), only 1 / 3-1 / 4 of the usual dose of mercaptopurine is used (decrease in metabolic rate due to xanthine oxidase blockade).
The daily dose of mercaptopurine is usually used once.
Also used in combination chemotherapy.
Side effects
From the nervous system and sensory organs: headache, weakness.
From the side of the cardiovascular system and blood: most often anemia, leukopenia, thrombocytopenia (during the period of active therapy for acute myelogenous leukemia in patients, a period of relative bone marrow aplasia is often noted, while it is important to carry out appropriate supportive treatment).
From the gastrointestinal tract: nausea, vomiting, diarrhea, loss of appetite, hepatotoxic effect (has a toxic allergic genesis and more often occurs when a dose is higher than 2.5 mg / kg / day) or cholestasis (scleral or skin yellowness) rarely - stomatitis ( usually at high doses), ulcerations in the digestive tract, hepatic encephalopathy.
From the genitourinary system: less often - hyperuricemia or nephropathy.
From the skin: hyperpigmentation of the skin, skin rash, itching.
Other: decreased immunity and susceptibility to infections.
Storage conditions
In the dark place at a temperature of no higher than 20 РC.
Term hodnosty
5 years
Deystvuyuschee substances
mercaptopurine
pharmacy terms of prescription
Form of Treatment
tablets
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review